Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-31 · accession 0001562180-25-000914 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-02-04 | 2025-01-31 | AKBA | Grund Nicholas | Chief Commercial Off | A - Grant | $0.00 | +194.9K | 498.2K | +64% | $0 |
| DT | 2025-02-04 | 2025-02-03 | AKBA | Grund Nicholas | Chief Commercial Off | S - Sale | $2.10 | -55.6K | 442.6K | -11% | -$116.8K |
| DT | 2025-02-04 | 2025-01-31 | AKBA | Grund Nicholas | Chief Commercial Off | A - Grant | $0.00 | +292.3K | 292.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | A | A | 194,900 | $0.00 | 498,200 | D | — | — | (F1) The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. |
| 2 | Common | Common Stock | 2025-02-03 | S | D | 55,621 | $2.10 | 442,579 | D | — | — | (F3) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2024. (F2) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. |
| 3 | Derivative | Stock Option (Right to buy) | 2025-01-31 | A | A | 292,300 | $0.00 | 292,300 | D | $2.24 · — to 2035-01-31 | 292,300 Common Stock | (F4) The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |